{"brief_title": "Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis", "brief_summary": "This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.", "condition": ["Postmenopausal Osteoporosis"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["AMG 162", "Placebo"], "description": ["60 mg/mL denosumab given day 1, month 6, month 12 and month 18", "Placebo given at day 1, month 6, month 12 and month 18"], "arm_group_label": ["AMG 162", "Placebo"], "criteria": "Eligibility Criteria - Postmenopausal women with Osteopenia (lumbar spine bone mineral density T-score between 1.0 and -2.5)", "gender": "Female", "minimum_age": "N/A", "maximum_age": "90 Years", "healthy_volunteers": "No", "keyword": "Postmenopausal", "mesh_term": ["Osteoporosis", "Osteoporosis, Postmenopausal", "Denosumab"], "id": "NCT00091793"}